This subproject represents an estimate of the percentage of the CTSA funding that is being utilized for a broad area of research (AIDS research, pediatric research, or clinical trials). The Total Cost listed is only an estimate of the amount of CTSA infrastructure going towards this area of research, not direct funding provided by the NCRR grant to the subproject or subproject staff. The University of Kansas Heartland Institute for Clinical and Translational Research (HICTR) was established in 2007 in response to the national CTSA initiative. The vision of the HICTR is to improve the health of Kansans by creating a novel and transformative translational research enterprise from bench to bedside to community. Particular strengths of our HICTR program are an entrepreneurial drug and device discovery and development program and a well-developed and highly accomplished community-based research program.
The specific aims of the HICTR are to: 1) create a new academic home with innovative training programs for clinical and translational Investigators;2) provide an enhanced coordinated translational research infrastructure;and 3) actively engage the community in developing, testing, and disseminating research, by capitalizing on and expanding existing networks, to improve the health of all Kansans?especially those in rural, underserved and other target communities. The proposed infrastructure and educational programs of the HICTR will address the challenges facing clinical and translational investigators by enhancing and integrating existing resources for easier access, developing new innovative resources, and capitalizing on resources residing in research centers across the university?including our KINBRE and five COBRE grants~and our HICTR network institutions. In support of our aims, we have marshaled an impressive array of institutional, corporate, and community resources in planning, developing, and establishing the HICTR. The HICTR will provide new infrastructure and training and educational programs to support investigators'clinical and translational research?taking laboratory discoveries to first trials in humans (Tl research) and moving research through to studies on dissemination and implementation of research findings to practice (T2 research). With extraordinary institutional and community support, we already have made tremendous progress. Funding from the CTSA program will allow the University of Kansas'HICTR the opportunity to fully realize its potential not only for our region, but also to contribute to the national CTSA Consortium.

Public Health Relevance

(See Instructions): The University of Kansas Heartland Institute for Clinical and Translational Research is an academic home for clinical and translational research, providing support to scientists and involving the community, so that discoveries and research findings wi|l be brought more rapidly to the point of care, thus improving the health of all Kansans.

Agency
National Institute of Health (NIH)
Institute
National Center for Research Resources (NCRR)
Type
Linked Specialized Center Cooperative Agreement (UL1)
Project #
1UL1RR033179-01
Application #
8365250
Study Section
Special Emphasis Panel (ZRR1-CR-1 (01))
Project Start
2011-06-01
Project End
2012-02-29
Budget Start
2011-06-01
Budget End
2012-02-29
Support Year
1
Fiscal Year
2011
Total Cost
$95,738
Indirect Cost
Name
University of Kansas
Department
Neurology
Type
Schools of Medicine
DUNS #
016060860
City
Kansas City
State
KS
Country
United States
Zip Code
66160
Weemhoff, James L; Woolbright, Benjamin L; Jenkins, Rosalind E et al. (2017) Plasma biomarkers to study mechanisms of liver injury in patients with hypoxic hepatitis. Liver Int 37:377-384
McCracken, Jennifer M; Chalise, Prabhakar; Briley, Shawn M et al. (2017) C57BL/6 Substrains Exhibit Different Responses to Acute Carbon Tetrachloride Exposure: Implications for Work Involving Transgenic Mice. Gene Expr 17:187-205
Kline, Timothy L; Korfiatis, Panagiotis; Edwards, Marie E et al. (2017) Image texture features predict renal function decline in patients with autosomal dominant polycystic kidney disease. Kidney Int 92:1206-1216
Gupta, Aditi; Mahnken, Jonathan D; Johnson, David K et al. (2017) Prevalence and correlates of cognitive impairment in kidney transplant recipients. BMC Nephrol 18:158
Lei, Yang; Mayo, Matthew S; Carlson, Susan E et al. (2017) Personalized Medicine Enrichment Design for DHA Supplementation Clinical Trial. Contemp Clin Trials Commun 5:116-122
Minai, Utako; Gustafson, Kathleen; Fiorentino, Robert et al. (2017) Fetal rhythm-based language discrimination: a biomagnetometry study. Neuroreport 28:561-564
Zhang, Chuanwu; Garrard, Lili; Keighley, John et al. (2017) Subgroup identification of early preterm birth (ePTB): informing a future prospective enrichment clinical trial design. BMC Pregnancy Childbirth 17:18
Shen, Chengli; Landsittel, Douglas; Irazabal, María V et al. (2017) Performance of the CKD-EPI Equation to Estimate GFR in a Longitudinal Study of Autosomal Dominant Polycystic Kidney Disease. Am J Kidney Dis 69:482-484
New, Jacob; Arnold, Levi; Ananth, Megha et al. (2017) Secretory Autophagy in Cancer-Associated Fibroblasts Promotes Head and Neck Cancer Progression and Offers a Novel Therapeutic Target. Cancer Res 77:6679-6691
Kandel, Sylvie E; Han, Lyrialle W; Mao, Qingcheng et al. (2017) Digging Deeper into CYP3A Testosterone Metabolism: Kinetic, Regioselectivity, and Stereoselectivity Differences between CYP3A4/5 and CYP3A7. Drug Metab Dispos 45:1266-1275

Showing the most recent 10 out of 120 publications